Please assess the completion status of the following clinical trial:

Trial Title: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Are male or female aged 18-55 years at the time of signing the informed consent form.~2. Have been diagnosed as having RA according to the revised 1987 American College of Rheumatology (ACR) criteria for at least 6 months prior to Screening.~3. Subjects who are considered by the Investigator to be a suitable candidate for self-administering adalimumab treatment~4. Must be able to provide informed consent, which must be obtained prior to any study related procedures.~Exclusion Criteria:~1. Have been treated previously with any biologic agents including any tumour necrosis factor inhibitor.~2. Have a known hypersensitivity to human immunoglobulin proteins or other components of SB5.~3. Have a current diagnosis of active tuberculosis (TB), have been recently exposed to a person with active TB, or are considered to have latent TB indicated by a positive QuantiFERON® Gold test result.~4. Have had a serious infection (such as sepsis, abscess, opportunistic infections or invasive fungal infection including histoplasmosis) or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to first dose of IP. Nonsignificant infections do not need to be considered exclusionary at the discretion of the Investigator.~5. Have a history of chronic or recurrent infection (such as chronic renal infection, chronic chest infection or recurrent urinary infection).~6. Have any of the following conditions:~   1. History of congestive heart failure (New York Heart Association Class III/IV)~  2. History of demyelinating disorders (such as multiple sclerosis or Guillain-Barré syndrome).~  3. History of any malignancy (other than lymphoproliferative disease and melanoma, see Exclusion Criteria 10.f) within the previous 5 years prior to Screening except completely excised and cured squamous carcinoma of the uterine cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.~  4. History of lymphoproliferative disease including lymphoma or melanoma.~  5. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SB5 40mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).